Products - Pulmonary fibrosis | Topic | NICE

Showing 10 products

Date | Title

Status: PublishedRemove ‘Status: Published’ filter

Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted (TA864)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 February 2023
Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 November 2021
Ex-situ machine perfusion for extracorporeal preservation of lungs (ex-vivo lung perfusion) for transplant (IPG695)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
26 May 2021
Pirfenidone for treating idiopathic pulmonary fibrosis (TA504)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
6 February 2018
Idiopathic pulmonary fibrosis in adults: diagnosis and management (CG163)
Product type:
Guidance
Programme:
Clinical guideline
Last updated:
23 May 2017
Published:
12 June 2013
Nintedanib for treating idiopathic pulmonary fibrosis (TA379)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 January 2016
Lung texture analysis for measuring interstitial lung diseases (MIB272)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
10 August 2021
Refractory extrapulmonary sarcoidosis: infliximab (ES4)
Product type:
Advice
Programme:
Evidence summary
Published:
17 January 2017
Pulmonary sarcoidosis: infliximab (ES2)
Product type:
Advice
Programme:
Evidence summary
Published:
20 December 2016
Idiopathic pulmonary fibrosis in adults (QS79)
Product type:
Quality standard
Published:
29 January 2015